Abstract:Angiogenesis plays a crucial role in the development of most solid tumours by delivering nutrients and oxygen to the tumour, and lung cancer, a highly vascular tumour. Over the past decade or so, inhibition of angiogenesis has been shown to be an effective and highly promising combination therapy option. Particularly, anti-vascular endothelial growth factor (VEGF) and anti-VEGF receptor therapies have been common strategies for cancer treatment. Combining anti-angiogenic therapy with other therapies, including chemotherapy, immunotherapy and targeted therapies, has been shown to be effective through the vascular normalisation effect induced by anti-angiogenic drugs. This article provides a review of the characteristics and mechanisms of tumour angiogenesis and anti-angiogenesis in combination with other therapies for the treatment of advanced non-small cell lung cancer.